Documents
Application Sponsors
Marketing Status
Prescription | 001 |
Prescription | 002 |
Application Products
001 | SOLUTION;INTRA-ARTERIAL | 99% (1ML) | 1 | ABLYSINOL | ALCOHOL |
002 | SOLUTION;INTRA-ARTERIAL | 99% (5ML) | 1 | ABLYSINOL | ALCOHOL |
FDA Submissions
TYPE 5; Type 5 - New Formulation or New Manufacturer | ORIG | 1 | AP | 2018-06-21 | STANDARD |
Submissions Property Types
CDER Filings
BPI LABS
cder:Array
(
[0] => Array
(
[ApplNo] => 207987
[companyName] => BPI LABS
[docInserts] => ["",""]
[products] => [{"drugName":"ABLYSINOL","activeIngredients":"ALCOHOL","strength":"99% (1ML)","dosageForm":"SOLUTION;INTRA-ARTERIAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"No"},{"drugName":"ABLYSINOL","activeIngredients":"ALCOHOL","strength":"99% (5ML)","dosageForm":"SOLUTION;INTRA-ARTERIAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"06\/21\/2018","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/207987lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"06\/21\/2018","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/207987lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2018\\\/207987Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2018\\\/207987Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2018-06-21
)
)